FibroBiologics (FBLG) Long-Term Debt Issuances (2026)
FibroBiologics (FBLG) posted quarterly Long-Term Debt Issuances of $327000.0 for Q1 2026, down 92.53% on a QoQ basis from $4.4 million in Q2 2025.
FibroBiologics (FBLG) Long-Term Debt Issuances (2026) Analysis & Trends
FibroBiologics has reported Long-Term Debt Issuances for 2 years, with the latest figure at $327000.0 in Q1 2026.
- Long-Term Debt Issuances for Q1 2026 came in at $327000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $4.7 million (changed N/A YoY), and the FY2025 annual result was $4.4 million, down 53.46% from the prior year.
- Long-Term Debt Issuances slipped to $327000.0 in Q1 2026, from $4.4 million in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $4.4 million in Q2 2025 and troughed at $327000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81,000.00 |
| Mar 31, 2026 | 81,000.00 |